Table 1:

Patient characteristics

Patient	Age (years)	Sex	Performance score	PAX-FOXO1 Fusion status	Disease sites at enrollment	Prior courses of XRT	Prior # systemic therapies	Dose level
1	8	Female	70	FN	Lung, pleura, abdomen, pelvis	2	4	1
2	12	Female	70	FN	Lung, pancreas, pelvis	2	4	1
3	19	Male	90	FP	Lung, mediastinal and hilar LN	1	3	1
4	8	Female	100	FN	Head and neck (temporal fossa)$	1	4	1
5^	19	Female	90	FP	Lung, pleura, mediastinal and hilar LN	2	2	1
6	11	Female	90	FP	Mediastinum, retroperitoneum, pelvis, bone	5	2	1
7	19	Female	90	FN	Retroperitoneum (paraaortic LN)	1	1	1
8^	8	Male	90	FN	Head and neck (parapharyngeal$	1	4	2
9	13	Male	100	FP	Lung, pleura, mediastinum	2	3	2
10	18	Male	100	FN	Pleura, mediastinum	1	1	2
11	29	Male	80	FP	Pleura, lung, bone, orbit	2	6	2
12	28	Male	80	FP	Pleura, mediastinum, bone marrow, muscle, pancreas, retroperitoneum, subcutaneous	2	3	2
13	24	Female	80	FP	Lung, pelvis	2	5	2
Summary*	18 (8–29)	6 Male/ 7 Female	90 (70–100)	6 FN ERMS/ 7 FP ARMS	2 Localized$/ 11 Metastatic	2 (1–5)	3 (1–6)	7 DL1/ 6 DL2

^{^}Not evaluable for toxicity;

^*Median (range) reported for age, performance score, prior courses of XRT, and prior # systemic therapies;

^$Local relapse of primary tumor. Abbreviations: XRT = radiation, FN = fusion negative, FP = fusion positive; DL= dose level